INOVIO Announces Participation in Scientific Conferences
AACR Special Conference in Cancer Research
INOVIO, a biotechnology company, will present a poster at the AACR Special Conference in Cancer Research on October 19, 2024. Dr. Matthew Morrow, VP of Translational Sciences at INOVIO, will present on the reduction in surgical interventions for the treatment of Recurrent Respiratory Papillomatosis by INO-3107. This treatment is associated with enriched macrophage, dendritic cell, and T cell signatures in patient airways.
ISV Congress 2024
Dr. Michael Sumner, Chief Medical Officer at INOVIO, will deliver an oral presentation and present a poster at the ISV Congress 2024 on October 22, 2024. The abstract title is “Clinical Assessment of Adjuvant Immunotherapy, INO-3107, in Adult Patients with Recurrent Respiratory Papillomatosis (RRP).”
Fall Voice Conference
Dr. Jeffrey Skolnik, SVP of Clinical Development at INOVIO, will present a poster at the Fall Voice Conference on October 25-26, 2024. The abstract title is also “Clinical Assessment of Adjuvant Immunotherapy, INO-3107, in Adult Patients with Recurrent Respiratory Papillomatosis (RRP).”
World Vaccine Congress Europe
Dr. Dave Liebowitz, SVP Early-Stage Clinical Development at INOVIO, will participate in a presentation and panel discussion at the World Vaccine Congress Europe on October 28, 2024. The focus will be on platform technologies in early-stage clinical development.
Abstracts from these conferences will be made available on INOVIO’s website following each presentation.
Impact on Individuals
Individuals who are affected by HPV-related diseases, cancer, and infectious diseases may benefit from the advancements in DNA medicines being developed by INOVIO. The presentations at scientific conferences showcase the progress being made in treatment options, potentially leading to improved outcomes and quality of life for patients.
Global Impact
INOVIO’s research and presentations at scientific conferences have the potential to impact the global healthcare landscape. By focusing on developing DNA medicines to address a range of diseases, including HPV-related diseases and cancer, the company is contributing to advancements in medical treatments that could benefit populations around the world.
Conclusion
INOVIO’s participation in scientific conferences highlights the company’s commitment to advancing DNA medicines for the treatment and prevention of various diseases. The research presented at these conferences has the potential to impact both individuals and the global healthcare community, paving the way for innovative treatment options and advancements in medical technology.
